Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

.2004 Aug 10;101(32):11640-5.
doi: 10.1073/pnas.0404641101. Epub 2004 Aug 2.

Inhibitor design by wrapping packing defects in HIV-1 proteins

Affiliations

Inhibitor design by wrapping packing defects in HIV-1 proteins

Ariel Fernández et al. Proc Natl Acad Sci U S A..

Abstract

Two viral proteins, HIV-1 protease and HIV-1 integrase, have been targeted for inhibitor design to prevent assembly and maturation of HIV-1 virions. The enzymatic mechanism of these proteins involves side-chain groups that serve as general acids or bases. Furthermore, catalytic activity requires that water be removed from the microenvironment surrounding the chemical reaction site or be constrained to serve as an activated nucleophile. Here, we identify previously unrecognized structural features that promote water removal from polar catalytic regions. Packing defects in the form of hydrogen bonds that are insufficiently dehydrated intramolecularly, named "dehydrons," are strategically placed in the structure to induce an anhydrous enzymatic pathway. Dehydrons become electrostatically enhanced and stabilized upon further desolvation. Thus, packing defects act synergistically with the polar active groups to enhance the enzymatic electrostatics. However, because dehydrons are sticky, they constitute targets for inhibitor design. We noticed that inhibitors attach to polar surfaces by further desolvating dehydrons, thus blocking the active sites or the sites involved in harnessing the substrate. The dehydrons are thus required for functional reasons, making them suitable targets. The differences in success when targeting HIV-1 protease, feline immunodeficiency virus protease, and HIV-1 integrase are rationalized in terms of the dehydron distribution, revealing possible improvements in the targeting strategy. Principles of design optimization are proposed to create an inhibitor that can be neutralized only at the expense of the loss of catalytic function. The possibility of using drugs that wrap dehydrons to block protein-protein associations is also discussed.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Distribution of dehydrons in HIV-1 protease monomer and dimer, flap asymmetry in the wrapping, and the inhibitor as a wrapper of packing defects. (a) Distribution of dehydrons in a monomeric HIV-1 protease unit. The backbone is represented as a light blue chain made up of virtual bonds joining α-carbons. Well wrapped backbone hydrogen bonds (seeMethods) are indicated as gray segments joining α-carbons, and dehydrons are marked in green. The catalytically active D25 is shown in black, and the most significant residues undergoing site mutation associated with drug resistance or substrate specificity are shown in red. The dehydrons, together with their functional roles, are as follows: (G49, G52), flap flexibility, dimerization inducer; (G78-T80), induces dehydration of catalytic core; (A28, R87), stickiness of substrate-harnessing region and dimerization inducer; (D29, N88), stickiness of substrate-harnessing region; and (T91, G94), dimerization inducer. (b) Homodimeric HIV-1 protease (PDB entry 1A30) adopting the same virtual-bond backbone representation as ina, except that one monomer is shown in red and the other is shown in blue. Only intermolecular wrapping is shown. Thus, the line joining the α-carbon of a residue in a monomer and the center of a backbone hydrogen bond on the other monomer indicates penetration upon dimerization of at least one nonpolar group of the residue side chain into the desolvation domain of the hydrogen bond. Some dehydrons become well wrapped hydrogen bonds upon dimerization. The remaining dehydrons dictate the pathway of the peptide-chain substrate through the HIV-1 protease. The substrate-anchoring residue D29 is marked in yellow, and the catalytic D25 is marked in black, as above. (c) Detail revealing the broken symmetry upon induced fit in HIV-1 dimerization. The flap angle defined by α-carbons at positions G51, G52, and F53 is distorted in one of the monomers to better wrap the flap dehydron of the other intermolecularly. (d) The tripeptide inhibitor EDL (red, residues 506–508) wrapping the dehydrons (G49, G52), (A28, R87), and (D29, N88) in one monomer of HIV-1 protease within the dimer (PDB entry 1A30). Only (D29, N88) remains a dehydron (green) even upon further wrapping provided by the inhibitor.
Fig. 2.
Fig. 2.
Packing defects in monomeric and dimeric (functional) FIV protease. (a) Dehydron distribution in FIV protease. The convention of Fig. 1 is followed. Mutation sites that affect substrate and inhibitor specificity (17) are marked in red if the substitution affects the wrapping of a dehydron and in yellow otherwise. (b) Dehydron distribution in the active dimeric FIV protease (PDB entry 3FIV). The intermolecular wrapping of dehydrons by L10 is highlighted. One monomeric chain (A) is depicted in red, and the other chain is depicted in blue. The color convention is the same as ina for dehydrons and the catalytic residue.
Fig. 3.
Fig. 3.
Packing defects in the stable fold of HIV-1 integrase. (a) Dehydron distribution for HIV-1 integrase (PDB entry 1B9F). The catalytic residues are marked in black, and the other active residues are marked in yellow. Dehydron (E152, K156), conventionally marked in green, constitutes a major epitope anchoring inhibitor drugs that dock along the major groove region parallel to the 146–164 helix. (b) Ribbon rendering of the HIV-1 integrase as a visual aid. Red, helices; blue, α-strands; light blue, turns and loopy regions. (c) The HIV-1 integrase positioned as in figure 4 of ref. , with the dehydrons (N117, N120) and (S119, T122) (a) defining the anchoring track for the viral DNA and the (E152, K156) defining the track for the host-cell DNA. The residue color convention is that ofa, and the virtual-bond chain is displayed in lighter blue for visualization purposes.
See this image and copyright information in PMC

References

    1. Fernández, A. & Scheraga, H. A. (2003) Proc. Natl. Acad. Sci. USA 100, 113–118. - PMC - PubMed
    1. Fernández, A. & Scott, R. L. (2003) Biophys. J. 85, 1914–1928. - PMC - PubMed
    1. Fernández, A. (2004) J. Mol. Biol. 337, 477–483. - PubMed
    1. Nemethy, G. & Scheraga, H. A. (1962) J. Chem. Phys. 36, 3382–3400.
    1. Nemethy, G. & Scheraga, H. A. (1962) J. Chem. Phys. 36, 3401–3417.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp